Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans

A single vaccination with MVA-NP+M1 boosts T-cell responses to conserved influenza antigens in humans. Protection against influenza disease and virus shedding was demonstrated in an influenza virus challenge study.

• Publication year

  2012

• Venue

  Clinical Infectious Diseases

• Publication date

  2012-03-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/cid/cis327PMID 22441650PMCID 3369564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.

  2012cited by this paper
• Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1

  2011cited by this paper
• Rapid Up-Regulation and Granule-Independent Transport of Perforin to the Immunological Synapse Define a Novel Mechanism of Antigen-Specific CD8+ T Cell Cytotoxic Activity1

  2009cited by this paper
• Electroporation of Synthetic DNA Antigens Offers Protection in Nonhuman Primates Challenged with Highly Pathogenic Avian Influenza Virus

  2009cited by this paper
• Influenza vaccine market dynamics

  2009influential reference
• Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA Antigens

  2008cited by this paper
• Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals.

  2008cited by this paper
• Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children

  2008cited by this paper
• Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine--Marshfield, Wisconsin, 2007-08 influenza season.

  2008cited by this paper
• Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.

  2006cited by this paper
• Cellular Immune Responses in Children and Adults Receiving Inactivated or Live Attenuated Influenza Vaccines

  2006cited by this paper
• Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

  2006cited by this paper
• Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus.

  2004cited by this paper
• DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

  2002cited by this paper
• Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus

  1995cited by this paper
• The human cytotoxic T cell response to influenza A vaccination.

  1981cited by this paper

• Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses

  2025cites this paper
• A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector.

  2024cites this paper
• Assessing Population-level Target Product Profiles of Broadly-protective Human Influenza A Vaccines

  2024cites this paper
• Opportunities and challenges for T cell-based influenza vaccines

  2024cites this paper
• Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review

  2024cites this paper
• Assessing population-level target product profiles of universal human influenza A vaccines.

  2024cites this paper
• Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing.

  2024cites this paper
• Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study.

  2024cites this paper
• Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy.

  2023cites this paper
• Truncation of NS1 Protein Enhances T Cell-Mediated Cross-Protection of a Live Attenuated Influenza Vaccine Virus Expressing Wild-Type Nucleoprotein

  2023cites this paper
• Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice

  2023cites this paper
• Nucleoprotein as a Promising Antigen for Broadly Protective Influenza Vaccines

  2023cites this paper
• Both Humoral and Cellular Immunity Limit the Ability of Live Attenuated Influenza Vaccines to Promote T Cell Responses.

  2023cites this paper
• Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs

  2023cites this paper
• Making Vaccines "On Demand" Making Vaccines "On Demand"

  2023cites this paper
• Neutrophil-to-lymphocyte ratio as a potential biomarker in predicting influenza susceptibility

  2022cites this paper
• Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses

  2022cites this paper
• Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications

  2022cites this paper
• Universal influenza vaccines are futile when benchmarked against seasonal influenza vaccines.

  2022cites this paper
• Development of a Universal Epitope-Based Influenza Vaccine and Evaluation of Its Effectiveness in Mice

  2022cites this paper
• Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

  2022cites this paper
• Understanding the Role of HLA Class I Molecules in the Immune Response to Influenza Infection and Rational Design of a Peptide-Based Vaccine

  2022cites this paper
• Controlled Human Infection Models To Accelerate Vaccine Development

  2022cites this paper
• The role of cell-mediated immunity against influenza and its implications for vaccine evaluation

  2022cites this paper
• Early vaccine‐mediated strain‐specific cytokine imbalance induces mild immunopathology during influenza infection

  2022cites this paper
• Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.

  2022cites this paper
• The race toward a universal influenza vaccine: Front runners and the future directions.

  2022cites this paper
• Next-generation T cell–activating vaccination increases influenza virus mutation prevalence

  2022cites this paper
• The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses—Not Just Another Brick in the Viral Nucleocapsid

  2022cites this paper
• MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination

  2022cites this paper
• Protective mucosal immunity against SARS-CoV-2 after heterologous systemic RNA-mucosal adenoviral vector immunization

  2021cites this paper
• Downstream processing for influenza vaccines and candidates: An update

  2021cites this paper
• MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination

  2021cites this paper
• Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

  2021cites this paper
• Advances in the design and development of SARS-CoV-2 vaccines

  2021cites this paper
• The Immune Correlates of Orthohantavirus Vaccine

  2021cites this paper
• Severity of heterosubtypic influenza virus infection in ferrets is reduced by live attenuated influenza vaccine

  2021cites this paper
• Universally Immune: How Infection Permissive Next Generation Influenza Vaccines May Affect Population Immunity and Viral Spread

  2021cites this paper
• Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)

  2021cites this paper
• Influenza Antigens NP and M2 Confer Cross Protection to BALB/c Mice against Lethal Challenge with H1N1, Pandemic H1N1 or H5N1 Influenza A Viruses

  2021cites this paper
• Efficacy of recombinant NPM 1 and NPM 1-CRT 3 DNA vaccines against Influenza A viruses in mice 4 C 57 / BL 6 5

  2021cites this paper
• Influenza vaccine: progress in a vaccine that elicits a broad immune response

  2021cites this paper
• Efficacy of recombinant NP-M1 and NP-M1-CRT DNA vaccines against Influenza A viruses in mice C57/BL6

  2021cites this paper
• Influenza vaccination in the elderly boosts antibodies against conserved viral proteins and egg-produced glycans.

  2021cites this paper
• Targeting Antigens for Universal Influenza Vaccine Development

  2021cites this paper
• Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice

  2021cites this paper
• T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine

  2021cites this paper
• Selecting and Using the Appropriate Influenza Vaccine for Each Individual

  2021cites this paper
• An Antigenic Thrift-Based Approach to Influenza Vaccine Design

  2021cites this paper
• Universal Vaccines against Influenza Viruses: Overview of the Past, Present, and Prospective

  2020influential citation
• New viral vectors for infectious diseases and cancer.

  2020cites this paper
• Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

  2020cites this paper
• Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine

  2020cites this paper
• Prospects and Challenges in the Development of Universal Influenza Vaccines

  2020cites this paper
• Vaccines from the Spanish Influenza as a firm foundation for new developments

  2020cites this paper
• Flu Universal Vaccines: New Tricks on an Old Virus

  2020cites this paper
• CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph

  2020cites this paper
• Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients

  2020cites this paper
• Next-generation influenza vaccines: opportunities and challenges

  2020cites this paper
• Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics

  2020cites this paper
• Impaired Cellular Immune Responses During the First Week of Severe Acute Influenza Infection.

  2020cites this paper
• Is a Universal Influenza Virus Vaccine Possible?

  2020cites this paper
• A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade

  2020cites this paper
• Multi-Epitope Peptide-Based and Vaccinia-Based Universal Influenza Vaccine Candidates Subjected to Clinical Trials

  2020cites this paper
• Immunity to Influenza: Closing in on a Moving Target

  2019cites this paper
• Current and future influenza vaccines

  2019cites this paper
• Memory T Cell Dynamics in the Lung during Influenza Virus Infection

  2019cites this paper
• Mouse Models Reveal Role of T-Cytotoxic and T-Reg Cells in Immune Response to Influenza: Implications for Vaccine Design

  2019cites this paper
• Novel IFN-γ ELISpot reveals robust T cell responses elicited after influenza nucleoprotein DNA vaccination in New Zealand White rabbits.

  2019cites this paper
• Development of a Universal Influenza Vaccine

  2019cites this paper
• Characterization of recombinant Modified Vaccinia virus Ankara expressing the Middle East respiratory syndrome coronavirus nucleocapsid protein

  2019cites this paper
• Universal influenza virus vaccines: what needs to happen next?

  2019cites this paper
• Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge

  2019cites this paper
• Heterosubtypic cross-protection correlates with cross-reactive interferon-gamma-secreting lymphocytes in the ferret model of influenza

  2019cites this paper
• Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice

  2019cites this paper
• Towards a universal influenza vaccine : generation and evaluation of vaccine formulations based on HA-epitopes in different influenza hosts

  2019cites this paper
• Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line

  2019cites this paper
• Meeting report and review: Immunological assays and correlates of protection for next‐generation influenza vaccines

  2019cites this paper
• Immunity to Influenza Infection in Humans.

  2019influential citation
• Dynamic Perspectives on the Search for a Universal Influenza Vaccine.

  2019cites this paper
• Modified Vaccinia Ankara–Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue

  2019cites this paper
• A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol

  2019cites this paper
• Novel Platforms for the Development of a Universal Influenza Vaccine

  2018cites this paper
• Distinct and complementary roles of CD4 T cells in protective immunity to influenza virus.

  2018cites this paper
• Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines

  2018cites this paper
• How far have we reached in development of effective influenza vaccine?

  2018cites this paper
• Workshop report: Experimental animal models for universal influenza vaccines.

  2018cites this paper
• Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine

  2018cites this paper
• Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine

  2018cites this paper
• Universal influenza vaccines: from viruses to nanoparticles

  2018cites this paper
• A Perspective on Nanoparticle Universal Influenza Vaccines.

  2018cites this paper
• Lessons along the Critical Path: Developing Vaccines against Human Helminths.

  2018cites this paper
• Vaccines for Improved Cellular Immunity to Influenza

  2018influential citation
• Epidemiology in History Universal InfluenzaVaccines: Progress inAchievingBroadCross-Protection In Vivo

  2018cites this paper
• Unanswered questions about the 1918 influenza pandemic: origin, pathology, and the virus itself.

  2018cites this paper
• Experimental infection of human volunteers.

  2018cites this paper
• KLRD1-expressing natural killer cells predict influenza susceptibility

  2018cites this paper
• Protection by universal influenza vaccine is mediated by memory CD4 T cells.

  2018cites this paper
• The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine

  2018cites this paper
• Clinical Advances in Viral-Vectored Influenza Vaccines

  2018cites this paper